Revised Intergrated Filing for the quarter and year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Caprolactam Chemicals Ltd has filed a revised integrated financial filing for FY25 (year ended March 31, 2025). Revenue from operations declined to Rs. 613.96 lakhs from Rs. 695.73 lakhs in FY24, a drop of about 12%. The company swung to a loss after tax of Rs. 70.87 lakhs versus a profit of Rs. 19.71 lakhs in the previous year, while Q4 FY25 alone posted a loss of Rs. 45.07 lakhs. Total expenses rose to Rs. 717.29 lakhs from Rs. 686.47 lakhs, squeezing margins sharply. Net cash from operating activities remained negative, and trade payables jumped dramatically to Rs. 871.34 lakhs from Rs. 43.77 lakhs. The auditor (Pulindra Patel & Co.) issued an unmodified opinion stating the results give a true and fair view.
Shareholders face a clear deterioration in fundamentals — a swing from profit to loss, shrinking revenue, and continued cash burn from operations are negative signals that could weigh on the stock. The sharp rise in trade payables also raises concerns about working capital stress and supplier credit dependency.